Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2008

View Archived Issues

Antinociceptive effects seen with TQ-1019 in models of painful HIV neuropathy

CG-100649 preclinical profile and phase I data described

Everolimus improves progression-free survival in metastatic renal cell carcinoma patients

New agents for cardiovascular disorders described in recent BioMarin and Suntory patents

Novel treatment option for HBV infection disclosed in recent patent

Remoxy oxycodone formulation effective in treating osteoarthritis pain

Delcath expands phase III percutaneous hepatic perfusion trial in melanoma

New glucocorticoid receptor modulator identified at GSK

ARYx announces successful results of chronic constipation trial with ATI-7505

Chemokine receives Hong Kong approval to initiate phase II CTCE-9908 trial

FDA grants fast track designation for OncoGenex's anticancer agent OGX-011

Human Genome Sciences initiates dosing in phase II HGS-ETR1 trial in NSCLC

Data on development of EHT-0202 for Alzheimer's disease presented

FDA approves Aloxi capsules for prevention of chemotherapy-induced nausea

FDA approves Nplate for adult chronic immune thrombocytopenic purpura

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...